

Clinical Pathology Laboratories

Drugs of Abuse Testing

Offering our clients state-of-the-art testing is part of CPL's ongoing commitment to excellence.

Effective 06/18/2018, Clinical Pathology Laboratories (CPL) will replace current drug of abuse (DAU) screening and screening with reflex confirmation profiles.

The new profiles provide:

- Reformulation and recombination of classes for profile testing, more relevant to current societal trends
- Standardization of drug thresholds to high sensitivity cutoff values
- Addition of the following analytes in specific profiles for testing:
 - Fentanyl
 - Buprenorphine
 - 6-Acetylmorphine
 - MDMA (Ecstasy)
- Expansion of testing for adulterants with disqualifying comments added to specimens determined to be altered
- Expansion of interpretive notes on reports regarding the method, cutoff values, and specific drugs that may or may not be detected by the screening method

New Profile Name	Order Code	Amphetamines	Barbiturates	Benzodiazepines	Cannabinoids	Cocaine	Oxycodone	Opiates	Phencyclidine	Methadone	Buprenorphine	Fentanyl	6-Acetylmorphine	MDMA/Ecstasy	EtOH
Drug of Abuse, 8 Analytes No Confirm	3305	X	X	X	X	X	X	X	X						
Drug of Abuse, 8 Analytes w/ Confirm	3306	X	X	X	X	X	X	X	X						
Drug of Abuse, 9 Analytes w/ EtOH, No Confirm	3316	X	X	X	X	X	X	X	X						X
Drug of Abuse, 9 Analytes w/ EtOH, w/ Confirm	3315	X	X	X	X	X	X	X	X						X
Drug of Abuse, 9 Analytes No THC or Confirm	3307	X	X	X		X	X	X	X	X	X				
Drug of Abuse, 9 Analytes No THC, w/ Confirm	3308	X	X	X		X	X	X	X	X	X				
Drug of Abuse, 10 Analytes No Confirm	3317	X	X	X	X	X	X	X	X	X	X				
Drug of Abuse, 10 Analytes w/ Confirm	3254	X	X	X	X	X	X	X	X	X	X				
Drug of Abuse, 11 Analytes w/ EtOH, No Confirm	3310	X	X	X	X	X	X	X	X	X	X				X
Drug of Abuse, 11 Analytes w/ EtOH, w/ Confirm	3311	X	X	X	X	X	X	X	X	X	X				X
Drug of Abuse, 13 Analytes No Confirm	3312	X	X	X	X	X	X	X	X	X	X	X	X	X	
Drug of Abuse, 13 Analytes w/ Confirm	3309	X	X	X	X	X	X	X	X	X	X	X	X	X	
Drug of Abuse, 14 Analytes w/ EtOH, No Confirm	3313	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Drug of Abuse, 14 Analytes w/ EtOH, w/ Confirm	3314	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Cutoff Values (ng/mL)		500	200	200	20	150	100	300	25	300	5	1	10	300	20

See reverse side for additional information.

Thank you for supporting



CLINICAL PATHOLOGY
LABORATORIES
A Sonic Healthcare Company

Additional information for the newly added analytes:

- Fentanyl: a potent synthetic opioid usually not detectable by standard opiate testing
- Buprenorphine: a semisynthetic opioid receptor partial agonist, used in place of or with methadone for detoxification or opioid replacement therapy
- 6-Acetylmorphine: a heroin metabolite, produced very quickly from the short-lived parent and detectable in the urine for approximately 8 hours after use
- MDMA (Ecstasy): a sympathomimetic stimulant related to amphetamine with significantly fewer CNS stimulant properties than methamphetamine

Testing to be eliminated from the screening and screen/reflex profiles:

- Methaqualone (Quaaludes): this drug was discontinued in the US in 1985; screening programs very rarely produce positive results, most of which are determined to be false positives
- Propoxyphene (Darvon): this drug was discontinued in the US in 2010 due to cardiac arrhythmias

The following order codes will be discontinued:

3202, 3203, 3204, 3205, 3206, 3210, 3211, 3212, 3220, 3225, 3250, 3251, 3255, 3258, 3270, 3272, 3285, 3290, 3295, 3296, 5813, 5867, 5869, and 5910.

Order code 3254, formerly known as DRUG ABUSE PANEL 10 WITH OXYCODONE will be modified as represented in the chart on reverse side.

The testing represents conventional drug of abuse screening using immunoassay (IA) methods and, where requested, reflex confirmation by chromatography with mass spectrometry. This IA technology is designed to react at a certain threshold to particular members of a drug class. For some classes certain compounds will not measure above the screen threshold. Additionally, chemically related compounds may trigger a "false positive" screen.

Confirmatory testing is performed for positive screens at an additional charge for those profiles designated "W/CONFIRM" on reverse side. Positive screens are reflexed and performed by a different technology, either gas chromatography with mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS or LC-MS/MS if tandem). The confirmatory testing provides higher sensitivity testing with lower thresholds, definitive analyte identification and quantitation without analytic false positives.

Additional test information:

Order Unit Code/Test Name:	See table on reverse side
Test Method:	Immunoassay Screen
Specimen Requirements:	50 mL Random Urine. No Preservative. Refrigerate.
Transport Temperature:	Refrigerated
Stability (collection to initiation of testing):	Ambient, 15-25°C: 1 week Refrigerated, 2-8°C: 1 week
Performed:	Monday through Friday / PM Shift
Analytic Time:	1 day
Reference Range:	Negative
CPT Code:	80307

Limited Coverage Test for Medicare. Advance Beneficiary Notice of Non-Coverage (ABN) required if diagnosis not covered.

Frequency Limit Test for Medicare. Advance Beneficiary Notice of Non-Coverage (ABN) is always required.

There must be documentation, by the clinician, in the patient's medical record, to support the medical necessity and frequency of drug testing on an individual basis.

Please contact your CPL Account Representative should you have any questions regarding this change.

Thank you for supporting

